In the Phase 2 obesity trial it produced about 24% weight loss at 12 mg over 48 weeks, the most of any drug in the class, and it cut liver fat by 86% in the people who started with fatty liver. In the 80-week Phase 3 obesity trial of 2,300 adults with an average BMI of 40, 12 mg produced 28% weight loss and 9 mg reached 26%
Discover additional information about BPC-157 products here
Your pleas for help will no longer fall on deaf ears
People with kidney disease, certain metabolic disorders, or allergies should avoid high-dose vitamin C injections
The Acetyl Code in Rheumatoid Arthritis and Other Rheumatic Diseases
Authorities approved it with brand names: Ozempic, Rybelsus, and Wegovy